氨甲环酸对创伤性脑损伤患者出血性病灶增长预防作用的随机双盲临床试验
这项随机双盲临床试验纳入149例CT证实的创伤性脑损伤伴颅内出血患者,随机接受氨甲环酸或安慰剂,24小时后复查CT评估出血变化。氨甲环酸组出血性病灶增长发生率为20.5%,安慰剂组为22.7%,差异无统计学意义(P=0.87,RR=0.89)。结论认为短期使用氨甲环酸未能显著预防创伤后出血性病灶增长或改善临床结局。
要点
- 氨甲环酸组出血性病灶增长发生率20.5%,安慰剂组22.7%,差异无统计学意义(P=0.87,RR=0.89)。
- 氨甲环酸组出血性病灶增长均值9.4(标准差15.3),安慰剂组10.2(标准差10.1),差异无统计学意义(P=0.27)。
- 氨甲环酸组死亡、出院时不良结局及3个月不良结局频率均低于安慰剂组,但差异均无统计学意义。
核心结论
- 短期使用氨甲环酸未能显著预防创伤后出血性病灶增长或改善临床结局。
研究设计与样本
- 随机双盲临床试验,纳入149例创伤性脑损伤且CT扫描显示任何类型颅内出血的患者,随机分配接受氨甲环酸或安慰剂。
- 24小时后复查CT评估出血变化、新发出血及血液对脑组织的占位效应,主要结局为出血性病灶增长。
主要发现
- 出血性病灶增长发生率氨甲环酸组20.5% vs 安慰剂组22.7%,差异无统计学意义(P=0.87,RR=0.89)。
- 出血性病灶增长均值氨甲环酸组9.4(标准差15.3)vs 安慰剂组10.2(标准差10.1),差异无统计学意义(P=0.27)。
- 死亡频率氨甲环酸组2.7% vs 安慰剂组4%,出院时不良结局氨甲环酸组10.8% vs 安慰剂组17.3%,3个月不良结局氨甲环酸组6.8% vs 安慰剂组14.7%,差异均无统计学意义。
- 未观察到氨甲环酸给药相关副作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intracranial hemorrhage is a common complication of traumatic brain injury (TBI). The purpose of this study is evaluation of the effect of tranexamic acid (TXA) on hemorrhagic mass growth in TBI patients. PATIENTS AND METHODS: In this randomized, double-blind clinical trial, 149 patients with TBI and any kind of blood on their computed tomography scan enrolled in the study and were randomly allocated to receive TXA or placebo. After 24 hours, computed tomography scan was repeated for assessing the changes in hemorrhage, new bleeding, and mass effects of blood on brain tissue. The primary outcome was growth of the hemorrhagic lesion. Data were analyzed by SPSS software using Fisher exact, chi-square, and Mann-Whitney U tests, as well as linear and logistic regression models. FINDINGS: The incidence of hemorrhagic lesion growth was 20.5% in the TXA group and 22.7% in the placebo group. The difference was not significant (P = 0.87, RR = 0.89). The mean (standard deviation) of hemorrhagic lesion growth was 9.4 (15.3) in the TXA group and 10.2 (10.1) in the placebo group without significant difference (P = 0.27). The frequency of deaths (2.7% vs. 4%), adverse outcome at discharge (10.8% vs. 17.3%), and 3 months later (6.8% vs. 14.7%) in the TXA group were lower than the placebo, but the difference was not statistically significant. No side effect was observed with the administration of TXA. CONCLUSION: Administration of a short dose of TXA does not lead to significant prevention of growth of posttraumatic hemorrhagic lesion or improvement of clinical outcomes.
引用
- Fakharian E, Abedzadeh-Kalahroudi M, Atoof F, et al. Effect of Tranexamic Acid on Prevention of Hemorrhagic Mass Growth in Patients with Traumatic Brain Injury. World Neurosurg. 2017. PMID: 29074420. doi:10.1016/j.wneu.2017.10.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。